CML real-world patient data for people with chronic CML
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic myeloid leukemia (CML)
- You can provide signed study consent (or consent is possible)
- You are not an allograft (donor transplant) patient who is not taking a TKI medicine
- If you had a donor transplant, you must be receiving a TKI treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how chronic myeloid leukemia (CML) affects your daily life and how care is organized in Lombardy hospitals. Researchers want to learn from your experiences to improve care for everyone with CML.
This trial is testing a new, highly sensitive blood test (digital PCR) to find BCR::ABL1 mutations in people with chronic-phase CML who are switching their tyrosine kinase inhibitor (TKI) because of resistance or a warning sign. The goal is to see if this test can help guide treatment decisions more precisely.
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This study reviews existing medical records of people with chronic myelogenous leukemia (CML) who were treated with specific FDA-approved targeted tablets (tyrosine kinase inhibitors) at MD Anderson but not on an MD Anderson clinical trial. It may help the hospital understand how these medicines are used in real-world care.
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.